COLUMBIA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that the Company will be added to Standard & Poor's MidCap 400 after the close of trading on Tuesday, March 1st. The S&P MidCap 400 is the most widely used index for mid-sized companies, according to Standard & Poor's.
"Martek is pleased to be added to the S&P MidCap 400 index. Inclusion in this popular index should broaden the company's exposure to investors," said Henry Linsert Jr., CEO of Martek.
The S&P MidCap 400 covers approximately 7% of the U.S. equities market, and is part of a series of S&P U.S. indices that can be used as building blocks for portfolio construction. Standard & Poor's reports that today mid- caps are recognized as an independent asset class, with risk/reward profiles that differ considerably from both large-caps and small-caps.
Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.
This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.
Contact: Beth Parker, Manager, Public Relations (443) 542-2551.
Martek Biosciences Corporation
CONTACT: Beth Parker, Manager, Public Relations of Martek BiosciencesCorporation, +1-443-542-2551